Menu Search
Equities

Pharming Group NV

PHGN:BRN

Pharming Group NV

Actions
  • Price (CHF)0.66
  • Today's Change0.00 / 0.00%
  • Shares traded9.99k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 03 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

  • Revenue in EUR (TTM)271.36m
  • Net income in EUR-16.93m
  • Incorporated1988
  • Employees415.00
  • Location
    Pharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
  • Phone+31 715247400
  • Fax+31 715247445
  • Websitehttps://www.pharming.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.